Novartis India Soars 20% on Rs 1,446 Crore Stake Sale to ChrysCapital

Introduction

Shares of Novartis India Ltd surged 20%, hitting the upper trading limit after its Swiss parent company, Novartis AG, announced the sale of its entire 70.68% stake in the listed Indian entity. The stake will be acquired by an investor consortium led by private equity firm ChrysCapital for a total of Rs 1,446 crore. The deal, announced on Friday, marks a significant strategic shift for Novartis AG and sets a new course for its Indian arm under new ownership.

The Transaction Details

Novartis AG entered into a share purchase agreement with a consortium comprising ChrysCapital, WaveRise Investments, and Two Infinity Partners. Under the terms of the agreement, the consortium will acquire Novartis AG's controlling stake, effectively taking over the company. This move is the result of a strategic business review initiated by the Swiss pharmaceutical giant in February 2024, aimed at transforming Novartis into a pure-play innovative medicines company globally.

The transaction is expected to close in the third quarter of 2026, subject to the fulfillment of customary closing conditions, including regulatory approvals. Upon completion, the ChrysCapital-led group will be classified as the new promoters of the company.

Mandatory Open Offer

As per regulations from the Securities and Exchange Board of India (SEBI), the acquisition triggers a mandatory open offer to public shareholders. The consortium has announced its intention to acquire an additional stake of up to 26% from the public. The open offer price has been set at Rs 860.64 per share, which could amount to an additional outflow of approximately Rs 552.5 crore if fully subscribed. This process allows public shareholders the option to exit their holdings following the change in management and control.

Strong Market Reaction

The market responded with strong optimism to the announcement. The stock of Novartis India zoomed 20% to close at its upper circuit limit of Rs 996.5 apiece on the BSE. This closing price was significantly higher than the open offer price of Rs 860.64, indicating that investors value the company more highly under the new ownership or anticipate a stronger growth trajectory. The benchmark Sensex, in contrast, rose by a modest 0.38% on the same day.

Strategic Rationale for Novartis AG

The divestment aligns with Novartis AG's global strategy to streamline its operations and focus on its core business of developing innovative medicines. The company stated that this sale completes its transformation into a focused medicines company and helps adapt its footprint for sustainable long-term growth.

However, Novartis is not completely exiting the Indian market. The company will continue its presence through its wholly-owned subsidiary, Novartis Healthcare Pvt Ltd (NHPL). This entity includes the commercial arm of Novartis in India, a corporate center in Hyderabad, and R&D teams involved in clinical trials across more than 300 sites in the country. The focus will be on expanding its innovative Cardio-Renal-Metabolic and Oncology portfolios.

Challenges and Performance of Novartis India

The decision to sell the stake comes at a time when Novartis India has been facing declining revenues. According to data from market tracker PharmaTrac, the company's annual sales value saw a gradual decline from Rs 655 crore as of December 2022 to Rs 493 crore by December 2025. A significant contributor to this decline was its blockbuster heart failure drug, Vymada, which went off-patent, leading to increased competition from generic alternatives. Sales of Vymada fell from Rs 258 crore to Rs 180 crore over the same period.

A New Chapter Under ChrysCapital

For ChrysCapital, one of India's largest private equity firms, this acquisition marks its first majority stake purchase in the pharmaceutical sector. The firm has a history of successful investments in the industry, including stakes in companies like Intas Pharma and Eris Lifesciences. The acquisition of Novartis India provides ChrysCapital with a controlling interest in an established company with a portfolio of well-known brands, including the painkiller Voveran.

As part of the agreement, Novartis India will be required to change its name within 120 days of the deal's completion to remove any association with the Novartis group. The new ownership is expected to bring a renewed focus on growth and operational efficiency.

Key Deal Metrics

Conclusion

The sale of Novartis AG's stake in its Indian listed arm is a strategic move that benefits both parties. It allows Novartis to focus on its global innovation pipeline while providing ChrysCapital with a platform to build a significant presence in the Indian pharmaceutical market. The immediate positive market reaction suggests investor confidence in the new leadership. The next steps will involve securing regulatory approvals and completing the open offer process, which will finalize the new ownership structure and set the stage for the company's future growth.